Literature DB >> 3490874

The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers.

C R Sheard, F Reilly, D E Tee, D Vergani, D Lowe, M Baum, A E Cameron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3490874      PMCID： PMC2001508          DOI： 10.1038/bjc.1986.230

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

1.  Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression.

Authors:  J F Hansbrough; E M Bender; R Zapata-Sirvent; J Anderson
Journal:  Am J Surg       Date:  1984-09       Impact factor: 2.565

2.  Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes.

Authors:  R C Bast; E L Reinherz; C Maver; P Lavin; S F Schlossman
Journal:  Clin Immunol Immunopathol       Date:  1983-07

3.  Augmentation of the human immune response by cyclophosphamide.

Authors:  D Berd; M J Mastrangelo; P F Engstrom; A Paul; H Maguire
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

4.  Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

Authors:  H C Maguire; V L Ettore
Journal:  J Invest Dermatol       Date:  1967-01       Impact factor: 8.551

5.  Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.

Authors:  D Berd; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

6.  Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.

Authors: 
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

7.  The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer.

Authors:  B G Brenner; G Friedman; R G Margolese
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

8.  T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease.

Authors:  D R McCluskey; A D Roy; W P Abram; W M Martin
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

9.  In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.

Authors:  H Ozer; J W Cowens; M Colvin; A Nussbaum-Blumenson; D Sheedy
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307
  10 in total
  4 in total

1.  Influence of adjuvant tamoxifen on blood lymphocytes.

Authors:  S Rotstein; H Blomgren; B Petrini; J Wasserman; L V von Stedingk
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

2.  Fatty acid modulation of antiestrogen action and antiestrogen-binding protein in cultured lymphoid cells.

Authors:  Y K Hoh; E H Lim; S O Ooi; O L Kon
Journal:  Experientia       Date:  1990-10-15

3.  The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene.

Authors:  R Valavaara; J Tuominen; A Toivanen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer.

Authors:  E Robinson; D Rubin; T Mekori; R Segal; S Pollack
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.